Emerging Markets Regulatory Tracker: Australia And China
This article was originally published in PharmAsia News
Australia ends a transition period for reclassification of joint replacements, while China has unveiled new drug and device manufacturing inspection rules and stricter local regulation of device clinical trials.
You may also be interested in...
India’s health ministry has laid out basic steps towards an overhaul of drug regulation at the local level, identifying a number of areas of concern.
China has released the results of back on proposed standards for the accreditation of clinical trial committees, investigators and sites.
China has finalized revised rules for the classification of medical devices, which will come into effect from the start of next year.